Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#121 / 200 Total
SYRE - Spyre Therapeutics Inc - Stock Price Chart
TickerSYRE [NASD, RUT]
CompanySpyre Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap921.63MEPS (ttm)-3.16
P/E-EPS this Y-8.65%
Forward P/E-EPS next Y-5.84%
PEG-EPS past 5Y44.65%
P/S-EPS next 5Y-5.20%
P/B2.55EPS Q/Q-106.83%
Dividend-Sales Q/Q-
Insider Own15.13%Inst Own93.76%
Insider Trans-0.08%Inst Trans21.13%
Short Float21.06%EarningsFeb 27/a
Analyst Recom1.30Target Price56.62
Avg Volume624.20K52W Range16.13 - 40.83
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Albers Jeffrey W.DirectorNov 06 '24Sale36.766,700246,31327,360Nov 08 04:53 PM
Albers Jeffrey W.DirectorOct 25 '24Sale36.4330010,92934,060Oct 28 04:41 PM
SESSIONS, LLCDirectorOct 25 '24Proposed Sale33.707,000235,900Oct 25 04:28 PM
Burrows Scott LChief Financial OfficerSep 03 '24Sale28.1718,531522,074116,422Sep 05 04:04 PM
Fairmount Funds Management LLCDirectorApr 25 '24Option Exercise0.003,639,68004,018,101Apr 25 04:55 PM
INDI - Indie Semiconductor Inc - Stock Price Chart
TickerINDI [NASD, RUT]
CompanyIndie Semiconductor Inc
CountryUSA
IndustrySemiconductor Equipment & Materials
Market Cap412.82MEPS (ttm)-0.75
P/E-EPS this Y52.68%
Forward P/E12.77EPS next Y193.64%
PEG-EPS past 5Y-
P/S1.91EPS next 5Y-
P/B0.98EPS Q/Q-98.98%
Dividend-Sales Q/Q-17.29%
Insider Own10.85%Inst Own91.09%
Insider Trans-1.84%Inst Trans17.09%
Short Float26.79%EarningsFeb 20/a
Analyst Recom1.25Target Price6.94
Avg Volume4.20M52W Range2.01 - 7.82
indie Semiconductor, Inc. is an autotech company, which engages in the provision of automotive semiconductor and software solutions for Advanced Driver Assistance Systems (ADAS) including LiDAR, connected car, user experience and electrification applications. Its technologies represent the core underpinnings of both electric and autonomous vehicles, while the advanced user interfaces transform the in-cabin experience to mirror and seamlessly connect to the mobile platforms. The company was founded by Donald McClymont, Ichiro Aoki, Scott Kee, and David Kang on February 9, 2007 and is headquartered in Aliso Viejo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McClymont DonaldChief Executive OfficerMar 06 '25Option Exercise0.00143,2500312,289Mar 10 07:02 PM
McClymont DonaldChief Executive OfficerMar 07 '25Sale2.9065,754190,687246,535Mar 10 07:02 PM
Aoki IchiroPresidentMar 06 '25Option Exercise0.006,250062,070Mar 10 07:01 PM
Aoki IchiroPresidentMar 07 '25Sale2.902,6057,55459,465Mar 10 07:01 PM
Wittmann MichaelChief Operating OfficerMar 06 '25Option Exercise0.0037,500080,582Mar 10 07:00 PM
CATX - Perspective Therapeutics Inc - Stock Price Chart
TickerCATX [AMEX, RUT]
CompanyPerspective Therapeutics Inc
CountryUSA
IndustryMedical Devices
Market Cap145.14MEPS (ttm)-1.21
P/E-EPS this Y-5.33%
Forward P/E-EPS next Y-15.55%
PEG-EPS past 5Y-9.86%
P/S100.10EPS next 5Y-9.76%
P/B0.48EPS Q/Q-54.00%
Dividend-Sales Q/Q-89.29%
Insider Own27.12%Inst Own68.21%
Insider Trans1.12%Inst Trans-2.32%
Short Float11.01%EarningsMar 26/a
Analyst Recom1.14Target Price15.18
Avg Volume771.81K52W Range2.01 - 19.05
Mar-31-25 07:00AM Perspective Therapeutics to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-26-25 04:10PM Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results (GlobeNewswire) -8.10%
Mar-17-25 07:00AM Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Feb-26-25 07:00AM Perspective Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-21-25 07:00AM Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 07:00AM Perspective Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire) +5.67%
Jan-24-25 12:18PM Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars (Benzinga) +10.47%
07:00AM Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
07:00AM Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-22-25 07:00AM Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Spoor Johan M.Chief Executive OfficerMar 28 '25Buy2.2422,02649,38459,383Apr 01 06:44 PM
Spoor Johan M.Chief Executive OfficerMar 28 '25Buy2.214,65010,2884,650Apr 01 06:44 PM
Williamson Robert F IIIDirectorMar 31 '25Buy2.1438,14581,775108,982Apr 01 05:04 PM
Williamson Robert F IIIDirectorMar 28 '25Buy2.2722,19250,37670,837Apr 01 05:04 PM
Graham JuanChief Financial OfficerMar 28 '25Buy2.2533,33374,94635,354Apr 01 05:03 PM
MBX - MBX Biosciences Inc - Stock Price Chart
TickerMBX [NASD, RUT]
CompanyMBX Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap229.29MEPS (ttm)-1.85
P/E-EPS this Y52.79%
Forward P/E-EPS next Y2.39%
PEG-EPS past 5Y-
P/S-EPS next 5Y19.16%
P/B0.89EPS Q/Q-53.17%
Dividend-Sales Q/Q-
Insider Own52.13%Inst Own50.08%
Insider Trans2.54%Inst Trans25.45%
Short Float28.55%EarningsMar 17/b
Analyst Recom1.00Target Price37.25
Avg Volume272.95K52W Range7.16 - 27.50
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORDON CARL LDirectorFeb 18 '25Buy10.84143,1701,551,9633,255,000Feb 19 05:56 PM
GORDON CARL LDirectorFeb 14 '25Buy9.8747,502468,7933,205,930Feb 19 05:56 PM
ORBIMED ADVISORS LLCDirectorFeb 18 '25Buy10.84143,1701,551,9633,255,000Feb 19 05:52 PM
ORBIMED ADVISORS LLCDirectorFeb 14 '25Buy9.8747,502468,7933,205,930Feb 19 05:52 PM
Hawryluk P. KentPresident & CEOFeb 04 '25Buy10.6950,000534,500448,277Feb 05 04:17 PM
ASMB - Assembly Biosciences Inc - Stock Price Chart
TickerASMB [NASD]
CompanyAssembly Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap70.45MEPS (ttm)-6.72
P/E-EPS this Y9.97%
Forward P/E-EPS next Y0.39%
PEG-EPS past 5Y31.58%
P/S2.47EPS next 5Y9.25%
P/B2.10EPS Q/Q21.45%
Dividend-Sales Q/Q2.71%
Insider Own47.32%Inst Own13.01%
Insider Trans37.99%Inst Trans9.97%
Short Float0.52%EarningsMar 20/a
Analyst Recom1.67Target Price33.50
Avg Volume27.28K52W Range9.56 - 19.93
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bjorkquist Jeanette MPrincipal Accounting OfficerMar 31 '25Sale9.851801,7734,617Apr 01 04:05 PM
Okazaki Jason ACEO and PresidentMar 31 '25Sale9.853553,49614,757Apr 01 04:05 PM
White Nicole SChief Manufacturing OfficerMar 31 '25Sale9.851971,94011,674Apr 01 04:05 PM
Houghton MichaelDirectorDec 30 '24Buy15.613,20249,9983,202Dec 31 04:24 PM
GILEAD SCIENCES, INC.10% OwnerDec 19 '24Buy21.37940,49920,098,4642,209,471Dec 23 08:26 PM
OPEN - Opendoor Technologies Inc - Stock Price Chart
TickerOPEN [NASD, RUT]
CompanyOpendoor Technologies Inc
CountryUSA
IndustryReal Estate Services
Market Cap727.14MEPS (ttm)-0.56
P/E-EPS this Y25.55%
Forward P/E-EPS next Y14.80%
PEG-EPS past 5Y33.36%
P/S0.14EPS next 5Y19.93%
P/B1.01EPS Q/Q-16.63%
Dividend-Sales Q/Q24.60%
Insider Own15.99%Inst Own50.26%
Insider Trans-1.25%Inst Trans-1.45%
Short Float11.53%EarningsFeb 27/a
Analyst Recom2.91Target Price1.47
Avg Volume42.94M52W Range1.01 - 3.09
Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schaub SydneyChief Legal OfficerMar 18 '25Sale1.145356071,618,576Mar 19 06:10 PM
WHEELER CARRIEChief Executive OfficerMar 17 '25Sale1.12561,237626,51213,536,875Mar 19 06:09 PM
SYDNEY SCHAUBOfficerMar 18 '25Proposed Sale1.19535637Mar 18 04:30 PM
Schaub SydneyChief Legal OfficerMar 17 '25Sale1.1287,47497,6481,619,111Mar 17 07:27 PM
Schaub SydneyChief Legal OfficerMar 03 '25Sale1.265,0006,2981,166,480Mar 04 04:43 PM
ACIU - AC Immune SA - Stock Price Chart
TickerACIU [NASD]
CompanyAC Immune SA
CountrySwitzerland
IndustryBiotechnology
Market Cap177.60MEPS (ttm)-0.58
P/E-EPS this Y-10.60%
Forward P/E-EPS next Y-27.89%
PEG-EPS past 5Y-
P/S5.64EPS next 5Y-
P/B1.45EPS Q/Q-211.76%
Dividend-Sales Q/Q-92.23%
Insider Own37.89%Inst Own27.84%
Insider Trans0.00%Inst Trans-8.78%
Short Float2.20%EarningsMar 13/b
Analyst Recom1.00Target Price10.08
Avg Volume180.98K52W Range1.87 - 4.98
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDREA M. A PFEIFEROfficerSep 27 '24Proposed Sale3.7040,000148,000Sep 27 04:26 PM
ANDREA M. A PFEIFEROfficerSep 18 '24Proposed Sale3.4620,00069,200Sep 18 04:40 PM
MODV - ModivCare Inc - Stock Price Chart
TickerMODV [NASD, RUT]
CompanyModivCare Inc
CountryUSA
IndustryMedical Care Facilities
Market Cap19.79MEPS (ttm)-14.15
P/E-EPS this Y-128.54%
Forward P/E2.22EPS next Y515.69%
PEG-EPS past 5Y-121.49%
P/S0.01EPS next 5Y46.51%
P/B-EPS Q/Q-344.19%
Dividend-Sales Q/Q-0.00%
Insider Own16.59%Inst Own101.46%
Insider Trans261.24%Inst Trans-11.19%
Short Float18.88%EarningsMar 06/a
Analyst Recom2.20Target Price5.45
Avg Volume631.63K52W Range1.31 - 32.82
Mar-31-25 08:05AM The 1-Minute Market Report March 30, 2025 (Seeking Alpha) -5.73%
Mar-28-25 09:24AM MODV Shareholders Have the Right to Lead the ModivCare Inc. Lawsuit - Contact the DJS Law Group to Discuss Your Rights - MODV (PR Newswire) -12.81%
07:55AM Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against ModivCare Inc. (MODV) (Newsfile)
Mar-26-25 07:55AM Scott+Scott Attorneys at Law LLP Reminds Investors a Securities Action Has Been Filed Against ModivCare Inc. (MODV) (Newsfile)
Mar-24-25 05:37AM ModivCare Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before March 31, 2025 to Discuss Your Rights MODV (GlobeNewswire) -8.49%
Mar-18-25 05:45AM ModivCare Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MODV (PR Newswire) +13.42%
Mar-17-25 06:34PM MODV Shareholders Have the Right to Lead the ModivCare Inc. Lawsuit - Contact the DJS Law Group to Discuss Your Rights - MODV (PR Newswire)
Mar-07-25 05:46AM ModivCare Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 31, 2025 to Discuss Your Rights - MODV (PR Newswire) -22.54%
Mar-06-25 04:23PM Modivcare Reports Fourth Quarter and Full Year 2024 Financial Results; Announces Changes to the Board of Directors (Business Wire) +5.65%
Feb-28-25 06:00AM Modivcare to Report Fourth Quarter and Full Year 2024 Financial Results and Adjourn Special Meeting to Follow Report (Business Wire) -18.01%
ModivCare, Inc. is a technology-enabled healthcare services company, which engages in the provision of a suite of integrated supportive care solutions for public and private payors and their members. It operates through the following segments: Non-Emergency Medical Transportation (NEMT), Personal Care, Remote Patient Monitoring (RPM), and Corporate and Other. The NEMT segment is involved in the non-emergency medical transportation programs for state governments and managed care organizations, or MCOs, in the U.S. The Personal Care segment offers home personal care services to State and Managed Medicaid, Medicare, and Private Pay patient populations in need of care monitoring and assistance performing activities of daily living. The RPM segment focuses on remote patient monitoring solutions, including personal emergency response systems, vitals monitoring, and data-driven patient engagement solutions. The Corporate and Other segment includes the costs associated with the company's corporate operations. The company was founded by Fletcher Jay McCusker in December 1996 and is headquartered in Denver, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AI Catalyst Fund, LP10% OwnerJan 31 '25Buy4.03187,500755,6251,942,500Feb 03 09:56 PM
AI Catalyst Fund, LP10% OwnerFeb 03 '25Buy3.87187,500725,6252,130,000Feb 03 09:56 PM
AI Catalyst Fund, LP10% OwnerJan 30 '25Buy4.3545,000195,7501,755,000Feb 03 09:56 PM
Coliseum Capital Management, L10% OwnerJan 10 '25Buy7.07720,0005,087,5863,702,751Jan 14 07:32 PM
Coliseum Capital Management, L10% OwnerJan 13 '25Buy6.56452,3782,967,6004,155,129Jan 14 07:32 PM
CLDI - Calidi Biotherapeutics Inc - Stock Price Chart
TickerCLDI [AMEX]
CompanyCalidi Biotherapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap14.53MEPS (ttm)-5.81
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q95.43%
Dividend-Sales Q/Q-
Insider Own7.06%Inst Own4.18%
Insider Trans-0.54%Inst Trans141.46%
Short Float2.64%EarningsMar 31/a
Analyst Recom1.50Target Price2.50
Avg Volume1.43M52W Range0.56 - 8.30
Mar-31-25 04:30PM Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -12.89%
04:10PM Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Mar-28-25 09:00AM Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -6.53%
Mar-26-25 08:00AM Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma (GlobeNewswire)
Mar-14-25 09:00AM Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +9.25%
Mar-11-25 02:00PM IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform (NewMediaWire)
Mar-10-25 08:00AM Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform (GlobeNewswire) -7.07%
Feb-28-25 09:00AM Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +5.56%
Feb-24-25 08:00AM Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital (GlobeNewswire) -7.52%
Jan-29-25 08:00AM Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 (GlobeNewswire)
Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Camaisa AllanCEO and Chairman of the BoardDec 17 '24Sale1.6210,00016,20066,712Dec 18 09:29 PM
Schoeneck James ADirectorJun 03 '24Option Exercise0.20548,000109,600963,887Jun 05 04:15 PM
VTYX - Ventyx Biosciences Inc - Stock Price Chart
TickerVTYX [NASD, RUT]
CompanyVentyx Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap76.11MEPS (ttm)-1.99
P/E-EPS this Y-2.09%
Forward P/E-EPS next Y6.84%
PEG-EPS past 5Y-87.13%
P/S-EPS next 5Y11.01%
P/B0.30EPS Q/Q47.62%
Dividend-Sales Q/Q-
Insider Own14.00%Inst Own78.65%
Insider Trans6.36%Inst Trans3.37%
Short Float11.30%EarningsFeb 27/a
Analyst Recom1.50Target Price8.67
Avg Volume1.25M52W Range1.13 - 5.88
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohan RajuCEO AND PRESIDENTMar 28 '25Option Exercise0.0011,84402,303,540Apr 01 04:36 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERMar 28 '25Option Exercise0.004,5310469,113Apr 01 04:35 PM
Nuss JohnCHIEF SCIENTIFIC OFFICERDec 27 '24Sale2.3621,11949,841464,582Dec 30 05:33 PM
Nuss JohnOfficerDec 27 '24Proposed Sale2.3621,11949,842Dec 27 04:46 PM
Gujrathi SheilaDirectorDec 23 '24Buy2.31130,000300,573130,000Dec 26 08:05 PM
18910111213141516171820